A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus
Latest Information Update: 20 May 2022
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors Tigercat Pharma; VYNE Therapeutics
- 20 Feb 2018 Results presented in a Menlo Therapeutics media release.
- 20 Feb 2018 Data assessing the safety and efficacy in this trial was published in the Journal of the American Academy of Dermatology, according to a Menlo therapeutics media release.
- 17 Feb 2018 Results published in the Journal of the American Academy of Dermatology